Jan 21, 2026
Early CMC readiness is a hot topic across pharma. Large companies, emerging biotech, and different modalities are facing the same pressure. Even in areas like radiopharmaceuticals, where constraints are more visible, the message holds to address CMC early or deal with it later under pressure.
Recent FDA activity reinforces this shift. With the CMC Development and Readiness Pilot and further strategy directions expected in 2026, there is a push toward earlier manufacturing readiness for accelerated programs. Similar fast-track approaches are emerging internationally, adding complexity for globally positioned teams.
In many early-stage programs, CMC is still treated as a later step. We see this often. Teams delay engagement, either to conserve resources or due to limited visibility into its impact. As a result, gaps appear in analytics, quality systems and documentation, or CDMO alignment creates friction and delay, most often causing the most damage when timelines tighten.
Programs like the FDA pilot enable earlier regulatory engagement, however, this only works when the underlying CMC strategy is already defined. Analytical planning, quality design, downstream development, timelines, and CDMO strategy need alignment upfront.
At Pharmefex, we support early biotech teams in building that structure. From CMC strategy and CDMO management to IND preparation and early FDA interaction, the focus is on enabling progress without unnecessary rework or delay.
Early FDA feedback helps. Early CMC engagement determines whether that feedback can be used effectively. We can help you along the way, regardless of where you are in the development phase. Contact us to learn how we might be able to help.Â
Sources
U.S. Food and Drug Administration Industry perspective on early CMC readiness across modalities
#CMC #Biotech #Pharma #DrugDevelopment #RegulatoryStrategy #IND #Pharmefex